9906436-2
IPOS copy —
for reference only.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/56, 31/65, 31/44, 31/335, 9/127

A1

(11) International Publication Number: **WO 99/49869**

(43) International Publication Date: 7 October 1999 (07.10.99)

(21) International Application Number: PCT/US99/04275

(22) International Filing Date: 26 March 1999 (26.03.99)

(30) Priority Data:
60/079,542 27 March 1998 (27.03.98) US

(71) Applicant *(for all designated States except US)*: PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KOPRESKI, Michael, S. [US/US]; 5121 Golden Eye Drive, Portage, MI 49024 (US). ASP, Beryl [SE/SE]; Hallandsgatan 3, S–254 76 Helsingborg (SE). FREDHOLM, Bo [SE/SE]; Larodstorpsvagen 5, S–254 84 Helsingborg (SE). GUNNARSSON, Per–Olv [SE/SE]; Gartnergatan 4, S–252 51 Helsingborg (SE).

(74) Agents: OBLON, Norman, F. et al.; Oblon, Spivak, McClelland, Maier & Neustadt, P.C., Suite 400, 1755 Jefferson Davis Highway, Arlington, VA 22202 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHODS TO POTENTIATE INTRAVENOUS ESTRAMUSTINE PHOSPHATE

(57) Abstract

Estramustine phosphate is an anti–mitotic chemotherapeutic drug with proven efficacy against cancer. The invention describes methods which potentiate the therapeutic benefit of intravenous estramustine phosphate. The invention provides for intravenous estramustine phosphate to be administrated at a high dosage exceeding 1300 mg as a single dose. Efficacious enhancement of estramustine phosphate pharmacokinetics is thereby achieved. Further provided, estramustine phosphate may be intravenously administered for use in combinational regimens with other chemotherapeutic agent. The therapeutic advantages achieved using the intravenous estramustine phosphate formulation are applicable to treatment of a variety of cancers including prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and other cancers.